Abstract: A system for one-touch split-mode conference access includes a server that transmits a first message associated with a conference with a client. A VOIP device displays a notification based on the first message. The VOIP device transmits a second message to transfer an audio component of the conference to the VOIP device. The audio component of the conference is continued on the VOIP device and the video component of the conference is retained on the client.

Abstract: A method for visualizing luminance variance for an object may include receiving image data associated with a digital image of the object. An algorithm is applied to the image data to generate an enhanced image. The enhanced image includes connected pixel value lines representative of pixel value ranges from the input image to enable visualization of luminance variance of the object by the human eye.

Abstract: A client is configured to control one or more functions of another client remotely via a wireless connection. Enabling control of the one or more functions of another client includes receiving a control command from a first client. The control command indicates a function to be performed by a second client. The control command is transmitted to the second client when a binding status indicates a binding between the first client to the second client.

Abstract: Methods for determining the presence or amount of a complex comprising a first and second molecular entity are provided, preferably an sFlt-1:PlGF complex. A determination of the presence or amount of the complex can be used in methods for predicting, detecting, monitoring a disease, or guiding therapy in respect to a disease such as vascular, vascular-related disease, cardiac, cardiac-related disease, cancer, cancer-related disease, preeclampsia, and preeclampsia-related disease. Determining sFlt-1:angiogenic factor complex is particularly useful for predicting and detecting preeclampsia in early stages of gestation and in stages of the disease where clinical evaluation may be uninformative.

Abstract: Polymer conjugates containing a C1-inhibitor having at least one substantially non-antigenic polymer covalently attached to the C1-inhibitor via amino group of the C1 inhibitor are provided. In the polymer conjugates, the substantially non-antigenic polymer is attached to the N-terminal of C1-inhibitor. Alternatively, the substantially non-antigenic polymer is attached to the N-terminal of C1-inhibitor and at least one more of the substantially non-antigenic polymer is attached to lysine and/or histidine of the C1-inhibitor. Furthermore, the polymer conjugates is attached to C1-inhibitor either via permanent or releasable spacers. In addition, methods of making the conjugates as well as methods of treatment using the conjugate of the present invention are also provided.

Abstract: Methods for determining the presence or amount of a complex comprising a first and second molecular entity are provided, preferably an sFlt-1:PlGF complex. A determination of the presence or amount of the complex can be used in methods for predicting, detecting, monitoring a disease, or guiding therapy in respect to a disease such as vascular, vascular-related disease, cardiac, cardiac-related disease, cancer, cancer-related disease, preeclampsia, and preeclampsia-related disease. Determining sFlt-1:angiogenic factor complex is particularly useful for predicting and detecting preeclampsia in early stages of gestation and in stages of the disease where clinical evaluation may be uninformative.

Abstract: Polymer conjugates containing a C1-inhibitor having at least one substantially non-antigenic polymer covalently attached to the C1-inhibitor via glycan group of the C1 inhibitor is provided. In addition, methods of making the conjugates as well as methods of treatment using the conjugate of the present invention are also provided.

Abstract: Polymer conjugates containing a C1-inhibitor having at least one substantially non-antigenic polymer covalently attached to the C1-inhibitor via thiol group of the C1 inhibitor is provided. In the polymer conjugates of the present invention, the substantially non-antigenic polymer is attached to either free thiol from a cysteine of thiol generated from disulfide bonds in C1 inhibitor. Alternatively, the substantially non-antigenic polymer is attached to one of more thiols in C1 inhibitor via bifunctional spacer. In addition, methods of making the conjugates as well as methods of treatment using the conjugate of the present invention are also provided.

Abstract: Methods for determining the presence or amount of a complex comprising a first and second molecular entity are provided, preferably an sFlt-1:PlGF complex. A determination of the presence or amount of the complex can be used in methods for predicting, detecting, monitoring a disease, or guiding therapy in respect to a disease such as vascular, vascular-related disease, cardiac, cardiac-related disease, cancer, cancer-related disease, preeclampsia, and preeclampsia-related disease. Determining sFlt-1:angiogenic factor complex is particularly useful for predicting and detecting preeclampsia in early stages of gestation and in stages of the disease where clinical evaluation may be uninformative.

Abstract: Methods of semiconductor processing are described. An experiment is designed for each process of a semiconductor substrate, which are implemented on respective multiple regions of the semiconductor substrate. A unique identifier is assigned to the semiconductor substrate. The respective design of experiment is implemented for each of the processes of the semiconductor substrate. Process criteria for each process is recorded, where the recording is associated with the assigned unique identifier. Process information is retrieved for each process, via its respective assigned unique identifier.

Abstract: Disclosed is a method comprising identifying one or more moving features in a first video via a computing platform, representing the one or more moving features as fingerprint representations via the computing platform, and comparing the fingerprint representations with fingerprint representations of a second video to determine a match via the computing platform.

Abstract: Subject matter disclosed herein relates to a method of detecting video content, and in particular, to a method of defining one or more digital fingerprints to identify video content.

Abstract: Biologically-active, interferon-beta 1b-polymer conjugate compositions are disclosed. The polymer portion is preferably a polyalkylene oxide polymer having a molecular weight of at least about 12 kDa. Methods of making and using the same are also disclosed.

Abstract: Methods for determining the presence or amount of a complex comprising a first and second molecular entity are provided, preferably an sFlt-1:PlGF complex. A determination of the presence or amount of the complex can be used in methods for predicting, detecting, monitoring a disease, or guiding therapy in respect to a disease such as vascular, vascular-related disease, cardiac, cardiac-related disease, cancer, cancer-related disease, preeclampsia, and preeclampsia-related disease. Determining sFlt-1:angiogenic factor complex is particularly useful for predicting and detecting preeclampsia in early stages of gestation and in stages of the disease where clinical evaluation may be uninformative.

Abstract: The present invention relates to polymer conjugates of SS1P, and methods of making using the same.

Abstract: The present invention relates to monovalent and multivalent single-chain antigen-binding polypeptides with site-specific modifications. The provided polypeptides are capable of being covalently linked or conjugated to polyalkylene oxides at the modified sites. The resulting conjugates retain antigen binding properties and exhibit prolonged circulating time and reduced antigenicity relative to unconjugated single chain antigen binding polypeptides. Methods and compositions for making and using the single chain antigen-binding polypeptides with site-specific modifications are also provided.

Abstract: The present invention relates to monovalent and multivalent single-chain antigen-binding polypeptides with site-specific modifications. The provided polypeptides are capable of being covalently linked or conjugated to polyalkylene oxides at the modified sites. The resulting conjugates retain antigen binding properties and exhibit prolonged circulating time and reduced antigenicity relative to unconjugated single chain antigen binding polypeptides. Methods and compositions for making and using the single chain antigen-binding polypeptides with site-specific modifications are also provided.